NCT07343271 Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
| NCT ID | NCT07343271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Oral Squamous Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-11 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-07-11 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The diagnostic and pre-therapeutic assessment of squamous cell carcinomas requires a neck and chest CT scan and a neck and facial MRI, which is the most effective examination, to establish the TNM stage of the tumor. However, obtaining this complete assessment can delay treatment. Confirmation of the non-inferiority of 40keV dual-energy CT in BOLT compared to MRI would spare the patient an additional MRI examination, speed up the pre-treatment assessment, reduce the loss of opportunity due to delayed treatment, and free up MRI imaging slots, which are still insufficient in the region.
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥18 years) * presenting with oral or oropharyngeal squamous cell carcinoma proven by histopathological analysis of a biopsy * having undergone a clinical examination with nasofibroscopy by an ENT surgeon specializing in cancer surgery * a contrast-enhanced cervicofacial MRI * and a contrast-enhanced cervicofacial DECT with BOLT maneuver. Exclusion Criteria: * A lesion other than oral or oropharyngeal squamous cell carcinoma * A labial location * A contraindication to performing one or both of the imaging examinations.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07343271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Oral Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07343271 currently recruiting?
Yes, NCT07343271 is actively recruiting participants. Contact the research team at philippe.schultz@chru-strasbourg.fr for enrollment information.
Where is the NCT07343271 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07343271 clinical trial?
NCT07343271 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 30 participants.